Core Viewpoint - The strategic technology licensing agreement between BGI Genomics and Swiss Rockets AG marks a significant step in BGI's globalization strategy, allowing the company to maximize the value of its CoolMPS sequencing technology while maintaining control over its core markets in Greater China and the Asia-Pacific region [1][2][3] Financial Arrangement - The agreement includes a total of at least $120 million in upfront payments, milestone payments, and a tiered revenue-sharing model based on net sales during the agreement period [1][2] - Swiss Rockets will pay a one-time upfront fee of $20 million and an additional $20 million in milestone payments, providing BGI with $40 million in guaranteed revenue that will improve cash flow without incurring R&D and commercialization costs in the European and American markets [2][5] Strategic Implications - The licensing agreement allows BGI to leverage Swiss Rockets' local advantages to bypass the challenges of independently entering the European and American markets, such as channel development and regulatory compliance, thus achieving global market penetration more efficiently [3][4] - BGI's strategy focuses on core technologies and assets while optimizing resource allocation by licensing out non-core technologies like CoolMPS, which complements its main product line [3][6] Market Context - Swiss Rockets is an innovative enterprise with several leading biotech companies under its umbrella, demonstrating significant progress in clinical research and commercial partnerships [4] - The transaction reflects a broader industry trend where Chinese life science companies are shifting from "product output" to "technology output," indicating a maturation of the sector [6] Valuation and Market Potential - An independent valuation report assessed the intangible assets related to CoolMPS at approximately $10.63 million, with North America and Europe accounting for $5.14 million and $2.58 million, respectively, supporting the pricing of the licensing agreement [6] - The licensing agreement is expected to positively impact BGI's future performance and enhance its global commercialization and profitability capabilities [6]

Core Viewpoint - BGI Genomics (688114.SH) has announced a strategic technology licensing agreement with Swiss Rockets AG, granting exclusive rights to its CoolMPS sequencing technology for global markets outside the Asia-Pacific and Greater China regions, with expected revenues of at least $120 million from upfront and milestone payments, as well as ongoing royalties based on net sales [1][2][6] Financial Improvement and Globalization Strategy - The core asset of the transaction is the global exclusive licensing of BGI's CoolMPS technology, while retaining operational rights in Greater China and parts of the Asia-Pacific, ensuring control over key markets [2][3] - The financial structure includes a $20 million upfront payment and a $20 million milestone payment, providing immediate cash flow improvement without incurring R&D costs in the European and American markets [2][5] - The agreement includes a royalty structure based on sales, allowing BGI to benefit from long-term cash flow while leveraging Swiss Rockets' market presence [2][3] Strategic Implications - The partnership allows BGI to utilize Swiss Rockets' local advantages to bypass the challenges of market entry in Europe and the U.S., achieving global technology deployment more efficiently [3][4] - BGI's strategy focuses on core technologies while monetizing non-core assets, enhancing resource allocation and market penetration [3][6] Validation of Technology Export Model - Swiss Rockets is an innovative enterprise with several leading biotech companies under its umbrella, demonstrating significant progress in clinical development and commercial partnerships [4] - The licensing agreement reflects industry standards, ensuring upfront returns and long-term revenue sharing, similar to other successful licensing deals in the biotech sector [5][6] - The independent valuation of BGI's CoolMPS technology at approximately $10.6 million supports the pricing of the licensing deal, indicating a fair market value [6]

Core Viewpoint - The strategic technology licensing agreement between BGI Genomics (MGI) and Swiss Rockets AG marks a significant step in BGI's globalization strategy, allowing for the exclusive licensing of its CoolMPS sequencing technology outside the Asia-Pacific and Greater China regions, with expected revenues of at least $120 million [1][2][6] Financial Improvement and Globalization Strategy - The agreement includes a $20 million upfront payment and a $20 million milestone payment, providing BGI with $40 million in certain revenue to improve cash flow without incurring R&D costs in the European and American markets [2][5] - The licensing model ensures ongoing royalty payments based on net sales, allowing BGI to leverage Swiss Rockets' local advantages for market penetration while maintaining control over its core markets [2][3] Technology Export Model and Growth Logic - The collaboration exemplifies a shift from "product output" to "technology output" for Chinese life science companies, validating BGI's technology platform's international competitiveness [6] - Swiss Rockets, as an innovative enterprise with multiple leading biotech companies, enhances the potential for successful commercialization of BGI's technology in the global market [4][6] Valuation and Market Positioning - An independent assessment valued BGI's CoolMPS intangible assets at approximately $10.6 million, with significant portions attributed to North America and Europe, supporting the transaction's pricing [6] - The licensing agreement is expected to positively impact BGI's future performance and enhance its global commercialization and profitability capabilities [6]

每经头条（nbdtoutiao）——万亿美元"世纪豪赌"！英伟达、OpenAI等巨头集体出手！循环融资靠谱 吗？专家：AI泡沫规模已是2008年全球房地产泡沫的4倍 （记者 王晓波） 每经AI快讯，华大智造10月12日晚间发布公告称，公司第二届第十七次董事会会议于2025年10月12日 以现场结合通讯方式召开。会议审议了《关于就CoolMPS测序技术签署授权许可协议暨受让与关联方相 关共有专利并进行授权收入分成的议案》等文件。 ...

Core Points - Company signed a licensing agreement with Swiss Rockets AG to grant exclusive rights to its CoolMPS sequencing technology and general sequencing technology for commercialization outside the Asia-Pacific and Greater China regions [1][2] - The agreement allows Swiss Rockets to develop and commercialize CoolMPS products while the company and its subsidiary will provide technical support and product development [2][3] - The licensing deal is expected to generate at least $120 million in licensing fees, improving the company's profitability and cash flow while allowing it to focus on its core Standard MPS technology [3] Licensing Agreement Details - The licensing agreement includes exclusive rights to CoolMPS technology and non-exclusive rights to general sequencing technology for CoolMPS product applications [2] - The company retains all rights in the Asia-Pacific and Greater China markets, enabling it to concentrate resources on core technologies and markets [3] - The agreement is aligned with the company's strategic direction, allowing for the monetization of technology without additional R&D investment [3] Financial Implications - The licensing agreement is projected to provide significant immediate profits and stable long-term cash flow, enhancing the company's financial position [3] - The expected licensing fees of no less than $120 million will contribute to improved profitability and cash flow [3]

Core Points - Company has signed a licensing agreement with Swiss Rockets AG to grant exclusive rights to its CoolMPS sequencing technology and general sequencing technology for commercialization outside the Asia-Pacific and Greater China regions [1][2] - The agreement allows Swiss Rockets to develop and commercialize CoolMPS products while the company and its subsidiary will provide technical support and product development [2][3] - The licensing deal is expected to generate at least $120 million in licensing fees, significantly improving the company's profitability and cash flow while allowing it to focus on its core technologies [3] Licensing Agreement Details - The licensing agreement includes exclusive rights to CoolMPS technology and non-exclusive rights to general sequencing technology for use in the CoolMPS product field [2] - The company retains all rights in the Asia-Pacific and Greater China markets, enabling it to concentrate resources on its Standard MPS technology and core markets [3] - The agreement is aligned with the company's strategic development direction, allowing for the realization of technology value without additional R&D investment [3] Financial Implications - The transaction is projected to yield significant immediate profits and long-term stable cash flow, enhancing the company's financial position [3] - The licensing fees from the agreement are expected to contribute positively to the company's overall profitability [3]

Core Viewpoint - BGI Genomics' subsidiary MGI US LLC and Complete Genomics, Inc. have signed a licensing agreement with Swiss Rockets AG to grant exclusive rights to CoolMPS sequencing technology and general sequencing technology outside the Asia-Pacific and Greater China regions [1] Group 1 - MGI LLC and CGI will provide technology transfer, product development, and commercialization support for the CoolMPS sequencing technology [1] - Swiss Rockets will be responsible for the development and commercialization of CoolMPS sequencing products [1] - The agreement includes exclusive licensing of patents, trade secrets, and trademarks related to CoolMPS technology for Swiss Rockets in specified global regions [1]

Core Viewpoint - The company BGI Genomics (688114) announced a licensing agreement with Swiss Rockets AG for its CoolMPS sequencing technology and general sequencing technology [1] Group 1 - BGI Genomics' wholly-owned subsidiary MGI US LLC and Complete Genomics, Inc. signed a licensing agreement with Swiss Rockets AG [1] - The agreement involves the paid licensing of CoolMPS sequencing technology and general sequencing technology, which includes underlying technologies for sequencing instruments, chips, and library reagents [1]

本报告依据中国资产评估准则编制 MGI US LLC 及 Complete Genomics, Inc. 拟对外授权使用无形资产涉及该无形资产价值 资产评估报告 北方亚事评报字[2025]第 01-1153 号 (共一册 第一册) 中国资产评估协会 资产评估业务报告备案回执 | 报告编码: | 4711020080202502094 | | --- | --- | | 合同编号: | GDDG[2025]第 2557 号 | | 报告类型: | 法定评估业务资产评估报告 | | 报告文号: | 北方亚事评报字[2025]第 01-1153 号 | | 报告名称: | MGI US LLC 及 Complete Genomics,Inc. 拟对外授 权使用无形资产涉及该无形资产价值资产评估报告 | | 评估结论: | 106,320,800.00美元 | | 评估报告日: | 2025年10月 09 | | 评估机构名称: | 北方亚事资 | | 签名人员: | 彭林浩 (资 T: 47220027 | | | 李巨林(资 = : 47100005 | | | (可扫描二维码查询备案业务信息) | 说明:报告备 ...

中信证券股份有限公司 关于深圳华大智造科技股份有限公司 就 CoolMPS 测序技术签署授权许可协议 暨受让与关联方相关共有专利并进行授权收入分成 的核查意见 上海证券交易所: 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为深圳华大智 造科技股份有限公司（以下简称"华大智造"或"公司"或"上市公司"）首次公开发 行股票并在科创板上市的保荐人。根据《证券发行上市保荐业务管理办法》、《上 海证券交易所科创板股票上市规则》等相关规定，中信证券履行持续督导职责， 对华大智造就 CoolMPS 测序技术签署授权许可协议暨受让与关联方相关共有专 利并进行授权收入分成事项进行了审慎核查，具体核查情况如下： 一、交易概述及审议程序 （一）本次交易的基本情况 1、CoolMPS 测序技术对外独占授权 公 司 全 资 子 公 司 MGI US LLC （ 以 下 简 称 "MGI LLC" ） 及 Complete Genomics,Inc（. 以下简称"CGI"）与 Swiss Rockets AG（以下简称"Swiss Rockets"） 签署《授权许可协议》（以下简称《许可协议》），将公司的 CoolMPS ...